We are live on ! Find out more
PC

Polar Capital Portfolio holdings

AUM $13.5B
1-Year Est. Return 55.9%
This Fund
S&P 500
This Quarter Est. Return
+3.49%
1 Year Est. Return
+55.9%
3 Year Est. Return
+127.44%
5 Year Est. Return
+269.08%
10 Year Est. Return
AUM
$6.26B
AUM Growth
+$473M
Cap. Flow
+$398M
Cap. Flow %
6.35%
Top 10 Hldgs %
23.68%
Holding
293
New
38
Increased
125
Reduced
71
Closed
38

Top Sells

Rank Stock Value
1
JNJ icon
Johnson & Johnson
JNJ
+$48.5M
2
MRK icon
Merck
MRK
+$37.3M
3
AMGN icon
Amgen
AMGN
+$35M
4
EW icon
Edwards Lifesciences
EW
+$29.3M
5
BAH icon
Booz Allen Hamilton
BAH
+$26.3M

Sector Composition

Rank Sector Weight
1 Financials 23.24%
2 Technology 21.39%
3 Healthcare 21.13%
4 Communication Services 9.82%
5 Industrials 4.95%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
AWH
76
DELISTED
Allied World Assurance Co Hld Lt
AWH
$25.9M 0.41%
482,500
+107,500
+29% +$4.94M
OXFD
77
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
$25.9M 0.41%
1,732,603
+239,420
+16% +$3.36M
TEL icon
78
TE Connectivity
TEL
$58.8B
$25.2M 0.4%
363,936
-15,855
-4% -$1.05M
CRUS icon
79
Cirrus Logic
CRUS
$6.74B
$25M 0.4%
441,375
+102,857
+30% +$5.69M
ACM icon
80
Aecom
ACM
$9.07B
$24.8M 0.4%
680,925
-481,947
-41% -$16M
CRTO icon
81
Criteo
CRTO
$1.03B
$24.7M 0.4%
602,216
+222,992
+59% +$8.69M
TMO icon
82
Thermo Fisher Scientific
TMO
$211B
$23.9M 0.38%
169,642
-47,764
-22% -$7.04M
RVTY icon
83
Revvity
RVTY
$12.3B
$23.7M 0.38%
455,000
+5,000
+1% +$261K
CCL icon
84
Carnival Corporation Ltd
CCL
$36.1B
$23.6M 0.38%
454,130
-2,727
-0.6% -$137K
RARE icon
85
Ultragenyx Pharmaceutical
RARE
$2.65B
$23.3M 0.37%
331,220
+89,500
+37% +$6.35M
ANET icon
86
Arista Networks
ANET
$219B
$23.1M 0.37%
3,824,544
+585,776
+18% +$3.28M
NBIX icon
87
Neurocrine Biosciences
NBIX
$17.7B
$23.1M 0.37%
597,256
+259,650
+77% +$11.8M
AKAO
88
DELISTED
Achaogen Inc
AKAO
$22.8M 0.36%
1,750,000
+1,605,000
+1,107% +$11M
MEOH icon
89
Methanex
MEOH
$4.32B
$22.6M 0.36%
515,014
-397,852
-44% -$15.9M
POWI icon
90
Power Integrations
POWI
$3.54B
$22.5M 0.36%
662,646
-237,668
-26% -$7.78M
RL icon
91
Ralph Lauren
RL
$22.2B
$22.5M 0.36%
248,794
+147,784
+146% +$15M
EGHT icon
92
8x8 Inc
EGHT
$247M
$22.3M 0.36%
1,562,151
-707,390
-31% -$10.3M
ABMD
93
DELISTED
Abiomed Inc
ABMD
$22.3M 0.36%
198,000
+70,000
+55% +$8.11M
NEWR
94
DELISTED
New Relic, Inc.
NEWR
$22.2M 0.36%
787,264
+219,331
+39% +$7.24M
TRV icon
95
Travelers Companies
TRV
$80.8B
$22.2M 0.35%
181,000
+55,000
+44% +$6.28M
HUBS icon
96
HubSpot
HUBS
$10.5B
$22.1M 0.35%
470,966
+13,717
+3% +$726K
MCK icon
97
McKesson
MCK
$98.5B
$21.9M 0.35%
156,007
XLNX
98
DELISTED
Xilinx Inc
XLNX
$21.9M 0.35%
362,074
+174,335
+93% +$9.37M
SYK icon
99
Stryker
SYK
$127B
$21.6M 0.34%
+180,000
New +$20.7M
WCN
100
Waste Connections
WCN
$42.8B
$21.3M 0.34%
407,003
-175,333
-30% -$8.86M

Similar funds

Polar Capital's Q4 2016 Portfolio in Review

As of Q4 2016, Polar Capital held 293 positions worth $6.26B, up 8.2% from $5.79B the previous quarter. Its ten largest holdings account for 24% of the portfolio.

Polar Capital deployed $398M of net new capital in Q4 2016, opening 38 new positions and adding to 125 existing holdings. Its largest new stake was Aetna Inc: 279,500 shares worth $34.7M.

By sector, the portfolio is most concentrated in Financials at 23% of assets, up from 20% a quarter earlier, followed by Technology and Healthcare.

On the sell side, the largest reduction was Johnson & Johnson, an estimated $48.5M trimmed.

  • Polar Capital's largest Q4 2016 buy was Aetna Inc: 279,500 shares worth $34.7M.
  • Polar Capital added most to Alexion Pharmaceuticals in Q4 2016, an estimated $53.8M increase.
  • Polar Capital's biggest Q4 2016 reduction was Johnson & Johnson, cutting an estimated $48.5M.
  • Polar Capital fully exited Edwards Lifesciences in Q4 2016, selling an estimated $29.3M.
  • Polar Capital's ten largest holdings make up 24% of its $6.26B portfolio in Q4 2016.
  • Polar Capital opened 38 new positions and closed 38 in Q4 2016.
  • Polar Capital's portfolio value rose 8.2% quarter-over-quarter to $6.26B.

Based on Polar Capital's 13F filing for Q4 2016, filed 14 Feb 2017.